US2006189536A1PendingUtilityA1

Treating the effects of nicotine

59
Assignee: MAYO FOUNDATIONPriority: Jul 18, 2002Filed: May 2, 2006Published: Aug 24, 2006
Est. expiryJul 18, 2022(expired)· nominal 20-yr term from priority
Inventors:Elliott RichelsonPaul FredricksonMona Boules
A61K 38/10A61K 31/137
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and materials for treating the effects of nicotine. In particular, the invention provides methods that involve administering a neurotensin receptor (NTR) agonist to a mammal that has been exposed to nicotine. The NTR agonist typically is administered in an amount effective to diminish or abolish the effects that nicotine has on the treated mammal. NTR agonists that can be used in methods of the invention include neurotensin (NT) polypeptide analogs such as NT69L. The invention also provides compositions containing an NTR agonist in combination with other agents used to help overcome nicotine effects such as sensitization and dependence. The compositions provided herein can be used to treat the effects of nicotine, including hyperactivity, hypothermia, respiratory distress, and hypertension.

Claims

exact text as granted — not AI-modified
1 . A composition comprising a neurotensin receptor agonist and a smoking cessation compound.  
     
     
         2 . The composition of  claim 1 , wherein said neurotensin receptor agonist is a polypeptide selected from the group consisting of NT(1-13), NT(8-13), NT69L, NT69L′, and NT76.  
     
     
         3 . The composition of  claim 1 , wherein said smoking cessation compound is bupropion.  
     
     
         4 . The composition of  claim 1 , further comprising a pharmaceutically acceptable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.